BioCentury
ARTICLE | Distillery Therapeutics

Gastrointestinal; cancer

November 27, 2017 6:45 PM UTC

Mouse studies suggest iron chelation or superoxide reduction could help treat colitis or colitis-induced colorectal cancer. In a mouse model of acute colitis, the iron-chelating agent Ferriprox deferiprone increased body weight and colon length and decreased histological changes and pathological scores compared with no treatment. In a mouse model of chronic colitis, Ferriprox decreased pathological scores. In a mouse model of colitis-induced colon cancer, Ferriprox or the superoxide scavenger tempol decreased tumor number, tumor burden and tumor cell proliferation. Next steps could include testing Ferriprox and tempol in additional models of colitis and colitis-induced colon cancer.

Apotex Inc. markets Ferriprox to treat iron overload and thalassemia...

BCIQ Company Profiles

University of Michigan

BCIQ Target Profiles

Fe ion